Cystic fibrosis medical therapy: Difference between revisions
Jump to navigation
Jump to search
| Line 25: | Line 25: | ||
| | | | ||
|- | |- | ||
| rowspan=" | | rowspan="3" |Airway surface rehydration | ||
|Hypertonic saline | |Hypertonic saline | ||
| | | | ||
|- | |- | ||
|Osmotic agents, mannitol | |||
| | | | ||
|- | |||
|Correction of ion transport | |||
| | |||
|- | |||
| rowspan="4" |Anti-infective agents | |||
|Prophylaxis | |||
| | |||
|- | |||
|Eradication | |||
| | | | ||
|- | |- | ||
| | |Suppression | ||
| | | | ||
|- | |||
|Acute exacerbations | |||
| | | | ||
|- | |- | ||
|Inflammation | | rowspan="4" |Inflammation | ||
|Anti-inflammatory agents | |||
| | | | ||
|- | |||
|Inhaled corticosteroids | |||
| | | | ||
|- | |- | ||
|CFTR protein defect | |LTB4 receptor antagonists | ||
|LTB4 phase II trials halted due to significant side | |||
effects | |||
|- | |||
|Azithromycin | |||
|Possible modulation of the inflammatory system | |||
|- | |||
| rowspan="2" |CFTR protein defect | |||
|Potentiators | |||
| | | | ||
|- | |||
|Correctors and combination | |||
therapy | |||
| | | | ||
|} | |} | ||
Revision as of 21:48, 13 February 2018
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Shaghayegh Habibi, M.D.[2]
|
Cystic fibrosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Cystic fibrosis medical therapy On the Web |
|
American Roentgen Ray Society Images of Cystic fibrosis medical therapy |
|
Risk calculators and risk factors for Cystic fibrosis medical therapy |
Overview
Medical Therapy
- Inhaled osmotic agent/ Hypertonic saline: Increase the airway fluid layer [1]
- Dornase alfa [recombinant human deoxyribo-nuclease (DNase)]: Cleave the extracellular DNA and aid airway clearance (DNA significantly increases the viscosity of the sputum) [2]
| Summary table of medical treatment in patients with Cystic fibrosis | ||
|---|---|---|
| Category | Approaches | Current status |
| Mucolytic agents | Dornase alfa | |
| N-acetyl-L-cysteine | ||
| Airway surface rehydration | Hypertonic saline | |
| Osmotic agents, mannitol | ||
| Correction of ion transport | ||
| Anti-infective agents | Prophylaxis | |
| Eradication | ||
| Suppression | ||
| Acute exacerbations | ||
| Inflammation | Anti-inflammatory agents | |
| Inhaled corticosteroids | ||
| LTB4 receptor antagonists | LTB4 phase II trials halted due to significant side
effects | |
| Azithromycin | Possible modulation of the inflammatory system | |
| CFTR protein defect | Potentiators | |
| Correctors and combination
therapy |
||
References
- ↑ Ratjen FA (2009). "Cystic fibrosis: pathogenesis and future treatment strategies". Respir Care. 54 (5): 595–605. PMID 19393104.
- ↑ Edmondson C, Davies JC (2016). "Current and future treatment options for cystic fibrosis lung disease: latest evidence and clinical implications". Ther Adv Chronic Dis. 7 (3): 170–83. doi:10.1177/2040622316641352. PMC 4907071. PMID 27347364.